Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Genfit maintains an active patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently facing 5 pending office actions. These actions are distributed across 3 distinct art units, indicating that the company's research and development efforts span several specialized technical subgroups relative to the 5 pending office actions.
The prosecution of these applications involves 5 distinct examiners, showing a high degree of diversification relative to the 5 pending office actions. Among them, NEWTON, CHAD A is identified as the busiest examiner, although this examiner is only responsible for 1 busiest examiner pending action relative to the 5 pending office actions. This distribution means that the busiest examiner's load is limited to 1 busiest examiner pending action, as the workload is spread across the group.
For patent practitioners, this data suggests a broad prosecution front where no single examiner dominates the portfolio. With 5 distinct examiners across 3 distinct art units, Genfit must manage multiple simultaneous legal dialogues. The 5 pending office actions in Biotechnology & Pharmaceuticals require a varied approach to satisfy the different requirements of each examiner involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (75%) |
| §103 only | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEWTON, CHAD A | 1 | 37.6% | +23.2% |
| ELKINS, BLAKE HARRISON | 1 | 100.0% | +0.0% |
| SABOUR, GHAZAL | 1 | 37.8% | +43.2% |
| LEE, ANDREW P | 1 | 48.3% | +23.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 43d overdue |
| 18378471 | SYSTEMS AND METHODS FOR PATIENT CLASSIFICATION | ELKINS, BLAKE HARRISON | — |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920260 | ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | LEE, ANDREW P | 71d overdue |
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 43d overdue |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | — |
| Art Unit | Apps |
|---|---|
| 3681 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18569619 | METHOD FOR NASH RISK ASSESSMENT IN PATIENTS HAVING A METABOLIC DISORDER | NEWTON, CHAD A | 3681 | §101§103§112 | Non-Final OA | 43d overdue | Pending | Dec 13, 2023 |
| 18378471 | SYSTEMS AND METHODS FOR PATIENT CLASSIFICATION | ELKINS, BLAKE HARRISON | — | §101§103§112 | Non-Final OA | — | Pending | Oct 10, 2023 |
| 18250990 | METHODS OF DIAGNOSTIC OF LIVER FIBROSIS | SABOUR, GHAZAL | — | §101§103§112DP | Non-Final OA | — | Pending | Apr 28, 2023 |
| 17920260 | ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS | LEE, ANDREW P | 1691 | §103 | Non-Final OA | 71d overdue | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial